Conbercept Intravitreal not checked
Chengdu Kanghong Biotech Co., Ltd.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- How it’s given
- “Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.”In the company’s words, NCT03630952 on ClinicalTrials.gov
- Tested for
- Neovascular Age-related Macular Degeneration (2 trials)
- Main trialPhase 3
- “The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.”In the company’s words, NCT03630952 on ClinicalTrials.gov
Other drugs for Neovascular Age-related Macular Degeneration
- Surabgene LomparvovecAbbVie · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
- ONS-5010Outlook Therapeutics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 10 Sep 2020 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) | |
| Phase 3Terminated | 25 Sep 2020 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026